Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20539727 | 1.00 | ARG1 (1.00) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL895146 | 0.98 | ARG1 (0.97) | ARG1ARG2 | |
| SCHEMBL22689266 | 0.89 | ARG1 (0.79) | ARG1ARG2 | |
| SCHEMBL27921023 | 0.87 | ARG1 (0.76) | ARG1ARG2 | |
| SCHEMBL1740434 | 0.87 | ARG1 (0.76) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL28034065 | 0.85 | ARG1 (0.74) | ARG1ARG2 | |
| SCHEMBL894172 | 0.85 | ARG1 (0.74) | ARG1ARG2 | |
| SCHEMBL13251255 | 0.85 | ARG1 (0.74) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL894740 | 0.84 | ARG1 (0.72) | ARG1ARG2 | |
| SCHEMBL28292422 | 0.83 | ARG1 (0.70) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2020-07-16 | — | — | US | claimed |
| EP-2389352-B1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2019-05-08 | — | — | EP | claimed |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2019-05-02 | — | — | US | claimed |
| US-10118936-B2 | Arginase inhibitors and methods of use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-11-06 | — | — | US | claimed |
| US-20160194340-A1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2016-07-07 | — | — | US | claimed |
| EP-2389352-A2 | ARGINASE INHIBITORS AND METHODS OF USE | The Trustees Of The University Of Pennsylvania (US) | 2011-11-30 | — | — | EP | claimed |
| US-8040818-B2 | Method for exchange of upkeep-relevant information with a computer-supported, upkeep system | ENDRESS + HAUSER PROCESS SOLUTIONS AG (CH) | 2011-10-18 | — | — | US | claimed |
| US-20100189644-A1 | ARGINASE INHIBITORS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-29 | — | — | US | claimed |
| WO-2010085797-A2 | ARGINASE INHIBITORS AND METHODS OF USE | THE TRUSTEES OF UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-29 | — | — | WO | claimed |
| WO-2024006841-A2 | COMPOSITIONS FOR WEIGHT LOSS AND CANCER TREATMENT | KNOWLEDGE PHARMACEUTICALS INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023283332-A1 | USES OF ARGINASE INHIBITORS FOR MANAGING KIDNEY DISEASE AND CARDIOVASCULAR CONDITIONS | EMORY UNIVERSITY (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20220296584-A1 | Membrane Active Molecules | KNOWLEDGE PHARMACEUTICALS INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3973997-A1 | MEMBRANE ACTIVE MOLECULES | Branequest, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | KNOWLEDGE PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | disclosed |
| US-8040818-B2 | Method for exchange of upkeep-relevant information with a computer-supported, upkeep system | ENDRESS + HAUSER PROCESS SOLUTIONS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20100189644-A1 | ARGINASE INHIBITORS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100189644-A1 | ARGINASE INHIBITORS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100189644-A1 | ARGINASE INHIBITORS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085797-A2 | ARGINASE INHIBITORS AND METHODS OF USE | THE TRUSTEES OF UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085797-A2 | ARGINASE INHIBITORS AND METHODS OF USE | THE TRUSTEES OF UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | ARG1 1/4885ARG2 2/4885 |
| US-10118936-B2 | Arginase inhibitors and methods of use | ARG1, ARG2, NOS2 | ARG1 1/4885ARG2 2/4885 |
| US-20220296584-A1 | Membrane Active Molecules | GABRP, GRIN3A, GRIN2A | ARG1 4334/4885ARG2 2061/4885 |
| US-20160194340-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, NOS2 | ARG1 1/4885ARG2 2/4885 |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | ARG1 1/4885ARG2 2/4885 |
| US-20200375958-A1 | MEMBRANE ACTIVE MOLECULES | GABRP, GRIN3A, GRIN2A | ARG1 4334/4885ARG2 2061/4885 |
| US-20100189644-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, NOS2 | ARG1 1/4885ARG2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.